Althea Chang

Try Jim Cramer's Action Alerts PLUS
CLICK HERE NOW

Bear Stalking Biotech Sector

08/02/05 - 03:16 PM EDT

Althea Chang

Amgen reported earnings that were 16 cents ahead of estimates, thanks to strong sales across several drug franchises, including Aranesp, Neulasta, Neupogen and Enbrel. Genentech topped estimates by 4 cents with the help of better-than-expected sales of Avastin and Herceptin. Genzyme also turned in a profit that was 4 cents better than estimates, thanks to gross margin improvements.

Schoenebaum views Amgen's ongoing pipeline positively, pointing to the experimental postmenopausal osteoporosis drug AMG-162 as an important drug in development. Additionally, he sees Genentech reporting solid second-half profits, buoyed by Avastin and Herceptin, despite possible manufacturing constraints.

Although he admits he doesn't love Genzyme, Schoenebaum sees an upside once 2006 arrives -- that's when the Medicare prescription drug program is expected to cover the kidney disease drug Renagel, and the analyst says the coverage isn't fully considered in to the company's sales projections.

Schoenebaum has a peer perform rating on Amgen. Genentech, Genzyme, Idenix (IDIX - Cramer's Take - Stockpickr) and Nabi (NABI - Cramer's Take - Stockpickr) are rated outperform.

Also, the analyst says that among the stocks with peer perform designations, he and his team "see modest potential upside this year" for MedImmune (MEDI - Cramer's Take - Stockpickr).

1 2
» Next

Althea Chang


07/28/05
Revenue Growth Brisk at Celgene

The company also reports better-than-expected earnings in the second quarter.


07/27/05
Big Growth Seen at Celgene

Analysts expect sales of the company's Thalomid to benefit from off-label use.


07/27/05
No Worries at Allergan

The drug company tops forecasts and raises its guidance.


08/05/08
Three Internet Stocks That Could Double

These forgotten Internet stocks are being accumulated by hedge funds.


08/15/08
The Five Dumbest Things on Wall Street

Raspberries for Apple; You'll be sorry, UBS; Fortress or Fort Knox? Wholly unappetizing Foods; give Liberty AOL or give them...


08/15/08
McCain Fund-Raising Picks Up

The GOP presidential candidate raised $27 million in July.


08/15/08
Cash-Back Cards Aren't Money in the Bank

Some credit and debit cards give you some cash back on purchases. But you need to manage it well to benefit from it.


Your Recent Quotes: Quote Up0 | Quote Down0
Dow S&P 500 NASDAQ
Oil*
Gold
10 Yr
0.00%
%
%
%
Data delayed 20 min
Sign up for our FREE newsletters now. See All

  • Cramer's Daily Booyah!
  • Before the Bell

Premium Stock Ideas
Access Action Alerts Plus to find out Cramer’s latest picks now!